144 related articles for article (PubMed ID: 34145985)
1. The effect of prior cancer on non-small cell lung cancer trial eligibility.
Herman M; Liu Z; Shepherd FA; Leighl N; Liu G; Bradbury PA
Cancer Med; 2021 Jul; 10(14):4814-4822. PubMed ID: 34145985
[TBL] [Abstract][Full Text] [Related]
2. Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.
Faehling M; Schwenk B; Kramberg S; Fallscheer S; Leschke M; Sträter J; Eckert R
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2059-2066. PubMed ID: 30062488
[TBL] [Abstract][Full Text] [Related]
3. Non-small-cell lung cancer after breast cancer: a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women.
Milano MT; Strawderman RL; Venigalla S; Ng K; Travis LB
J Thorac Oncol; 2014 Aug; 9(8):1081-90. PubMed ID: 25157761
[TBL] [Abstract][Full Text] [Related]
4. Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients.
Budnik J; DeNunzio NJ; Singh DP; Milano MT
Clin Lung Cancer; 2020 May; 21(3):195-203. PubMed ID: 30914310
[TBL] [Abstract][Full Text] [Related]
5. Impact of prior cancer on eligibility for lung cancer clinical trials.
Gerber DE; Laccetti AL; Xuan L; Halm EA; Pruitt SL
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25253615
[TBL] [Abstract][Full Text] [Related]
6. Does intensive follow-up alter outcome in patients with advanced lung cancer?
Benamore R; Shepherd FA; Leighl N; Pintilie M; Patel M; Feld R; Herman S
J Thorac Oncol; 2007 Apr; 2(4):273-81. PubMed ID: 17409797
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
[TBL] [Abstract][Full Text] [Related]
9. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
10. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
Al-Baimani K; Jonker H; Zhang T; Goss GD; Laurie SA; Nicholas G; Wheatley-Price P
Curr Oncol; 2018 Aug; 25(4):e291-e297. PubMed ID: 30111974
[TBL] [Abstract][Full Text] [Related]
11. Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?
Lim C; Sung M; Shepherd FA; Nouriany N; Sawczak M; Paul T; Perera-Low N; Foster A; Zawisza D; Feld R; Liu G; Leighl NB
J Thorac Oncol; 2016 Jan; 11(1):79-84. PubMed ID: 26762742
[TBL] [Abstract][Full Text] [Related]
12. Variable impact of prior cancer history on the survival of lung cancer patients.
Monsalve AF; Hoag JR; Resio BJ; Chiu AS; Brown LB; Detterbeck FC; Blasberg JD; Boffa DJ
Lung Cancer; 2019 Jan; 127():130-137. PubMed ID: 30642541
[TBL] [Abstract][Full Text] [Related]
13. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
Pruitt SL; Laccetti AL; Xuan L; Halm EA; Gerber DE
Br J Cancer; 2017 Mar; 116(6):717-725. PubMed ID: 28196065
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of lung cancer after a previous malignancy.
Reinmuth N; Stumpf P; Stumpf A; Muley T; Kobinger S; Hoffmann H; Herth FJ; Schnabel PA; Bischoff H; Thomas M
Respir Med; 2014 Jun; 108(6):910-7. PubMed ID: 24650574
[TBL] [Abstract][Full Text] [Related]
15. Stage III non-small-cell lung cancer: Establishing a benchmark for the proportion of patients suitable for radical treatment.
Al-Shamsi HO; Al Farsi A; Ellis PM
Clin Lung Cancer; 2014 Jul; 15(4):274-80. PubMed ID: 24685356
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study.
Hoppe BS; Henderson R; Pham D; Cury JD; Bajwa A; Morris CG; D'Agostino H; Flampouri S; Huh S; Li Z; McCook B; Nichols RC
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):517-522. PubMed ID: 26774428
[TBL] [Abstract][Full Text] [Related]
17. Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website.
Subramanian J; Madadi AR; Dandona M; Williams K; Morgensztern D; Govindan R
J Thorac Oncol; 2010 Aug; 5(8):1116-9. PubMed ID: 20592626
[TBL] [Abstract][Full Text] [Related]
18. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
19. The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials.
Clarey J; Kao SC; Clarke SJ; Vardy J
Ann Oncol; 2012 May; 23(5):1229-1233. PubMed ID: 21986095
[TBL] [Abstract][Full Text] [Related]
20. Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
Brule SY; Al-Baimani K; Jonker H; Zhang T; Nicholas G; Goss G; Laurie SA; Wheatley-Price P
Lung Cancer; 2016 Jul; 97():15-21. PubMed ID: 27237022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
